J

Johnson & Johnson

Makes prescription drugs and medical devices

Production Planning and Logistics Lead

Full-TimeUpdated Deadline 11/5/26
No salary listed
Expert
Bachelor's, Master's
Ciudad Juárez, Chihuahua, Mexico
In Person
Operations & LogisticsProduction Planning & Scheduling, Supply Chain Management

About the job

Requirements
  • A bachelor's degree is required, preferably in Business, Supply Chain, Engineering, Information Technology, Logistics, or Operations.
  • At least 8 years of experience in Supply Chain, Operations, or other business work is required.
  • Production planning or manufacturing experience in medical devices or pharmaceuticals is required.
  • Analytical and quantitative skills, including high proficiency in Microsoft Excel, are required.
  • The ability to identify problems or issues, recommend appropriate solutions, and follow up to ensure positive results is required.
  • Experience with Material Requirements Planning (MRP), Advanced Planning and Scheduling (APS), or Enterprise Resource Planning (ERP) systems is required.
  • Strong communication, interpersonal, and presentation skills are required.
  • Proficiency in Microsoft Office, including Excel, Word, Access, Outlook, and PowerPoint, is required.
  • Compliance with applicable federal, state, local, and company regulations, policies, and procedures is required.
  • Following company guidelines for health, safety, and environmental practices is required.
Responsibilities
  • Create and publish weekly detailed production programs consistent with the Master Production Schedule, established capacity and material, production restrictions, and related work-center programs.
  • Maintain planning parameters for assigned products in JDE within established inventory policies and maintain JDE to ensure proper functioning of MRP.
  • Monitor daily production activities against plans using reports and physical inspection of the production floor.
  • Maintain priorities and expedite production-in-process availability as needed to maximize customer service; coordinate with purchasing, production, engineering, master planning, quality, and other departments to address activities that could put the production program at risk.
  • Create a balanced supply plan that drives production signals to meet customer and warehouse inventory requirements, working with Operations to manage capacity and absorption.
  • Plan and create weekly MRP for raw materials and components for suppliers and buyers to execute.
  • Manage purchase orders and buying, ensure continuous product flow, address invoice and mismatch issues, partner with suppliers to confirm order quantities and delivery dates, and track supplier performance.
  • Meet site inventory targets and follow inventory governance processes by providing projections, bridges, and tracking, and implementing optimal safety-stock settings.
  • Oversee weekly MRP, translating the finished-goods supply plan into raw-material requirements for buyer analysis and execution.
  • Lead the monthly Supply Sales and Operations Planning meeting and prepare materials presenting metrics, requirements, and production strategies for each production line to leadership and cross-functional teams.
  • Analyze and monitor inventory levels against business-plan goals and avoid obsolete or surplus materials.
  • Communicate with planners and buyers at sibling plants and approve and coordinate material shipments to other plants when necessary.
  • Work with engineering to support production orders for evaluations and validations in the area.
  • Participate in developing production programs to support new-product launches.
  • Maintain business indicators, including scorecards, metrics, and run-strategy charts.
  • Support buyers in resolving invoice mismatches and respond to product-related questions and special requirements.
  • Perform administrative tasks, including preparing information for reports.
  • Guide less experienced planners.
  • Plan and monitor work-order supplies and returnable budgets.
  • Communicate business-related issues or opportunities to the next management level.
  • Perform assigned duties and provide backup support to the team as required.
  • Ensure that the role's personal and company activities comply with applicable health, safety, environmental, regulatory, policy, and procedural requirements.
  • If supervising or managing staff, ensure subordinates follow applicable health, safety, and environmental guidelines and that necessary resources are available and in good condition.
Desired Qualifications
  • A master's or postgraduate degree is preferred.
  • Experience in planning, purchasing, or materials management is preferred; experience with demand, inventory, or supply planning is highly preferred.
  • APICS certification is preferred.
  • Experience with Manugistics, JDE, or SAP is preferred.
  • Scenario-planning experience is preferred.
  • Preferred skills include analytical reasoning, consulting, controls compliance, Corrective and Preventive Action (CAPA), demand forecasting, demand planning, developing others, distribution management, inclusive leadership, leadership, manufacturing flow management, organizing, performance measurement, product design, production operations, product lifecycle management (PLM), supply planning, team management, and workflow analysis.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.